MOMENTUM: Phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor

Momelotinib (MMB) is an oral JAK1/2 and ACVR1/ALK2 inhibitor that has shown clinical activity in myelofibrosis (MF). This phase 3 study (MOMENTUM trial) evaluated responses to MMB vs. Danazol on key symptoms, anemia and spleen volume response at 24 weeks in MF patients who had previously been treated with a JAK inhibitor. The results showed that MMB was superior to Danazol in improving symptoms, reducing transfusion requirements, and spleen responses while having comparable safety data.